Insurance hurdles worsen delays, force abandoned treatments, and result in hospitalizations and deaths, radiation oncologists report nationwide.
A new survey by the American Society for Radiation Oncology (ASTRO) confirmed that delays in prior authorizations cause significant harm to patients with cancer, leading to treatment delays, abandoned treatments, hospitalizations, and even deaths.1
“These survey findings confirm what radiation oncologists witness daily: prior authorization policies are failing people with cancer, causing avoidable delays that are dangerous and, in too many cases, deadly,” said Howard M. Sandler, MD, FASTRO, chair of the ASTRO board of directors, in a statement.
More than 1 million people in the US receive radiation therapy each year to treat cancer and other diseases, but restrictive prior authorization practices are creating significant challenges for patients and clinics.2 In the latest ASTRO survey, conducted in the fall of 2024, more than 750 physicians from across the US shared their experiences, representing academic (47%) and private (51%) practices in diverse communities, including urban (49%), suburban (39%), and rural (13%) areas.
The online survey was sent to 4601 radiation oncologists in the US, with 754 respondents.
The findings reveal that restrictive prior authorization policies are not only harming people with cancer but also intensifying the strain on clinic staff, with the problem worsening in recent years.
Nearly a third (30%) of radiation oncologists reported that prior authorization has caused emergency department visits, hospitalization, or permanent disability for their patients, and 7% said it has led to or contributed to a patient’s death.1 Widespread delays were also common, with nearly all respondents (92%) indicating that prior authorization causes treatment delays for their patients, affecting more than a third (35%) on average.
Alarmingly, more than two-thirds (68%) reported that these delays last 5 days or longer, a significant increase from 52% in 2020, with such delays linked to higher risks of cancer progression, complications, and death.
Additionally, one-third of physicians (33%) said prior authorization has led to patients abandoning radiation treatment, with 1 in 10 patients on average discontinuing care. More than 8 in 10 doctors (82%) said they were forced to resort to less optimal treatments more frequently than in prior surveys. Barriers extend to obtaining medications critical for managing the adverse effects of cancer treatment, with issues reported for nausea drugs (23%), erectile dysfunction aids (18%), prescription skincare (17%), and pain management medications (40% for opiates and 10% for nonopiate pain relief).
Radiation oncologists overwhelmingly noted that the burden of prior authorization has worsened, with 85% reporting an increase in the past 3 years. Nearly all (94%) said it exacerbates staff burnout, while 80% had to reallocate staff time to manage the process, and 60% needed to hire additional staff. The majority (54%) reported that more than half of their cases require prior authorization, up from 44% in 2019. While 71% of requests are initially approved, 73% of denied cases are overturned on appeal, illustrating inefficiencies in the process. Concerns about peer reviews also persist, as only 66% of peer-to-peer consultations are conducted by radiation oncologists, with systemic flaws such as a lack of transparency, decision-making authority, and inflexible scheduling further delaying patient care.
“The ASTRO-supported Improving Seniors’ Timely Access to Care Act of 2024 (S.4532, H.R.8702) would bring much-needed reform to prior authorization for Medicare Advantage plans, such as establishing a real-time process for coverage decisions,” said Sandler, in a statement. “We encourage Congress to act now to help end these life-threatening delays and put Medicare Advantage on a path toward transparency and accountability by passing this legislation before the current session ends.”
References
1. New ASTRO survey finds that prior authorization delays lead to serious harm for people with cancer. ASTRO. News release. December 3, 2024. Accessed December 4, 2024. https://www.newswise.com/articles/new-astro-survey-finds-that-prior-authorization-delays-lead-to-serious-harm-for-people-with-cancer
2. How prior authorizations harm cancer care. ASTRO. December 3, 2024. Accessed December 4, 2024. https://www.astro.org/ASTRO/media/ASTRO/News%20and%20Publications/PDFs/PriorAuthSurvey_2024ExecutiveSummary.pdf
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines
September 6th 2025National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American College of Chest Physicians (CHEST) offer complementary yet distinct frameworks for lung cancer care, reflecting differences in evidence evaluation, regional adaptation, and policy integration.
Read More
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines
September 6th 2025National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American College of Chest Physicians (CHEST) offer complementary yet distinct frameworks for lung cancer care, reflecting differences in evidence evaluation, regional adaptation, and policy integration.
Read More
2 Commerce Drive
Cranbury, NJ 08512